![[logo] HealthTree Foundation](https://static.healthtree.org/icons/icon_spinner.svg){kind=icon}
![[logo] HealthTree Foundation](https://static.healthtree.org/logo_icon_only.svg){kind=icon}
Clinical Trial: Nivolumab, Lenalidomide, and Dexamethasone In High-Risk Smoldering Multiple Myeloma
This research study is evaluating a new immunotherapy drug called "nivolumab" as a possible treatment for smoldering multiple myeloma in order to prevent or postpone development of active multiple myeloma. - Patients with smoldering multiple myeloma do not have symptoms but are at risk for progressing to active multiple myeloma. Multiple myeloma is a cancer of the plasma cell, which is an important part of the immune system. Patients with active multiple myeloma generally require treatment.
What treatments are used in this trial?
- Dexamethasone ( Steroid )
- Lenalidomide ( Immunomodulatory Drugs (IMID) )
- Nivolumab ( Checkpoint Inhibitor , Immunotherapy , Monoclonal Antibody )
There are 9 active sites including: City of Hope (southern CA), Pacific Cancer Care (northern CA), Colorado Blood Cancer Institute, Winship Cancer Institute (Georgia), Dana Farber Cancer Institute (MA), Beth Israel Deaconess Medical Center (MA), University of Michigan (MI), Barbara Ann Karmanos Cancer Institute (MI), Sarah Cannon (TN).
To learn more about this trial and sign up to receive notifications, click here:
This research study is evaluating a new immunotherapy drug called "nivolumab" as a possible treatment for smoldering multiple myeloma in order to prevent or postpone development of active multiple myeloma. - Patients with smoldering multiple myeloma do not have symptoms but are at risk for progressing to active multiple myeloma. Multiple myeloma is a cancer of the plasma cell, which is an important part of the immune system. Patients with active multiple myeloma generally require treatment.
What treatments are used in this trial?
- Dexamethasone ( Steroid )
- Lenalidomide ( Immunomodulatory Drugs (IMID) )
- Nivolumab ( Checkpoint Inhibitor , Immunotherapy , Monoclonal Antibody )
There are 9 active sites including: City of Hope (southern CA), Pacific Cancer Care (northern CA), Colorado Blood Cancer Institute, Winship Cancer Institute (Georgia), Dana Farber Cancer Institute (MA), Beth Israel Deaconess Medical Center (MA), University of Michigan (MI), Barbara Ann Karmanos Cancer Institute (MI), Sarah Cannon (TN).
To learn more about this trial and sign up to receive notifications, click here:
Study of the CD38 Antibody Daratumumab Clinical Trial To find all eligible clinical trials, click here: Study of the CD38 Antibody Daratumumab Clinical Trial
about the author
Jennifer Ahlstrom
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can contribute to cures by joining HealthTree Cure Hub and joining clinical research. Founder and CEO of HealthTree Foundation.
More on Navigating Your Health
Trending Articles
Get the Latest Multiple Myeloma Updates, Delivered to You.
By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.
Education
News Articles Patient Guides My Journal University Expert Webinars Find a Specialist HealthTree PodcastCommunity
Connect Coach Moves All Events Community Support Groups Black Myeloma Health Resources in SpanishCure Hub
HealthTree Cure Hub Find Side Effects Solutions See Tracked Labs Connect Medical Records Treatment Options Twin Machine Clinical Trial FinderFollow Us
HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.
Copyright © 2025 HealthTree Foundation. All rights reserved.
Tax ID 45-5354811